137 results about "Metabolic function" patented technology

The invention discloses a synthetic microbial agent for treating uranium-contaminated soil and a preparation method of the synthetic microbial agent. The synthetic microbial agent is prepared from the following bacteria: P.adami, P.megatherium, bacillus subtilis, Artobacter volluticus, symbiotic fungi, Aspergillus niger, sulfate reducing bacteria and Shewanella. The symbiotic fungi are mucor lastein, mucor unimingguminum, mucor circinelloides, mucor dense, rhizopus arrhizus and phylum phthochytrium parasitic fungi. The prepared synthetic microbial agent and synthetic microbial embedded balls are applied to uranium-contaminated soil remediation, the key enzyme activity can be effectively improved, the soil metabolism function is enhanced, meanwhile, exchangeable uranium with high ecological risk is converted into stable and low-harm residual uranium, the mobility and bioavailability of uranium in soil are effectively weakened, and the uranium-contaminated soil remediation effect is improved. Therefore, immobilized remediation of uranium is realized, and a good soil uranium fixing effect is achieved.

The invention relates to the technical field of medical assistance, in particular to a depression risk assessment method and system based on intestinal flora characteristics. The method comprises the following steps: acquiring an individual enteric microorganism sample, performing nucleic acid sequencing on the enteric microorganism sample, and determining abundance data of functional genes related to a neural activity metabolic pathway in enteric microorganisms; carrying out metabolite detection on the intestinal microorganism sample, and determining concentration data of metabolites related to the neural activity metabolic pathway in the intestinal microorganisms; based on the abundance data of the functional genes and the concentration data of the metabolites, data fusion processing is carried out, a neural activity metabolism function spectrum is constructed, and the neural activity metabolism function spectrum is a multi-dimensional feature vector; and inputting the neural activity metabolic function spectrum into a pre-trained risk assessment model, and outputting a depression risk score of the individual. The accuracy and repeatability of evaluation are remarkably improved, and the method has great potential for early screening, dynamic monitoring and personalized health management.

The invention provides a single strain metabolism characteristic chromatogram database of oral key microorganisms in a high-glucose microenvironment and a construction method and application thereof, and belongs to the technical field of oral microbiology. The method comprises the following steps: simulating an intraoral high-glucose microenvironment in vitro; the method comprises the following steps: carrying out standardized single-strain culture on oral key microorganisms, carrying out whole-spectrum metabolism detection (non-targeted liquid chromatography-mass spectrometry (LC-MS) and non-targeted gas chromatography-mass spectrometry (GC-MS) on culture supernatant, and identifying and analyzing metabolism to construct a single-strain metabolism characteristic spectrum database of the oral key microorganisms in a high-glucose microenvironment. The database can be used for source attribution and cross validation of in-vivo metabolome results, and assists in screening key metabolites and key pathways related to high glucose. According to the method, the reliability of metabolite source judgment is improved, the directional influence of high glucose on the flora metabolism function is revealed, the method is standardized, and resources are platformized.

The invention belongs to the technical field of bioengineering and microbiomics, and particularly relates to an acquisition method and application of a specific metabolic substrate of lactobacillus crispatus and application of a specific carbohydrate active enzyme CAZzyme gene and a polysaccharide utilization site (PUL). Genomes of lactobacillus crispatus and lactobacillus inertus are obtained from a public database, gene annotation is carried out on the genomes of the lactobacillus crispatus and the lactobacillus inertus, and a random forest model and a KEGG metabolic pathway diagram are combined to find specific CAZzyme genes, PUL and other genes with metabolic functions of the lactobacillus crispatus; a substrate which only lactobacillus crispatus can metabolize is searched based on the genome difference of the two bacteria, and the ability of the obtained substrate for promoting the growth of lactobacillus crispatus and inhibiting the growth of inert lactobacillus is evaluated through experiments. Growth and reproduction of the lactobacillus crispatus are promoted through the substrates, so that the lactobacillus crispatus accounts for a higher proportion in vagina microecology, the vagina is protected, and reproduction of other unfavorable bacteria is reduced. The assisted reproduction success rate is improved.

This invention provides a method for monitoring and evaluating the risk of pathogenic bacteria transmission in poultry farm feces, belonging to the field of livestock and poultry biosecurity control technology. The method includes evaluating the risk of Salmonella transmission during the poultry physiological cycle, assessing the risk of antibiotic resistance associated with drug administration behavior, and monitoring the function during composting based on microbial community structure and metabolic function. This invention can accurately locate the highest-risk nodes of pathogen contamination and antibiotic resistance evolution during the breeding cycle, solving the problem of inaccurate identification of risk sources in existing technologies and avoiding poultry product contamination due to missed risk assessments. It overcomes the single-dimensional limitation of existing technologies that only detect the quantity of pathogens, comprehensively evaluating pathogen risk from phenotypic, molecular, and functional levels. The assessment results are more in line with the actual biosecurity needs of poultry farming, ultimately reducing the safety risks of poultry product contamination and the spread of antibiotic resistance.

Provided are novel compounds for GIPR, GLP-1R and GCGR. Specifically, provided are GLP-1R / GIPR / GCGR triagonists peptides, and conjugates comprising an Fc fragment and GLP-1R / GIPR / GCGR triagonists peptides. Pharmaceutical compositions comprising these compounds,as well as uses thereof in treating metabolic conditions and disorders, such as diabetes mellitus, type 2 diabetes, obesity, metabolic dysfunction-associated fatty liver disease (MAFLD), non-alcoholic fatty liver disease (NAFLD), metabolic dysfunction-associated steatohepatitis (MASH), and non-alcoholic steatohepatitis (NASH) are also provided.

The application discloses an Akkermansia muciniphila branched-chain amino acid metabolism gene nifJ and application thereof in colostrum IgA synthesis, and belongs to the technical field of genetic engineering. The application finds through in-vivo and in-vitro tests that the nifJ is a branched-chain amino acid metabolism gene of the Akkermansia muciniphila, regulates the metabolism process from branched-chain amino acids to branched-chain short-chain fatty acids, and plays a key role in the synthesis of maternal colostrum IgA. The research result of the application is expected to clarify the interaction relationship between the metabolic function of the Akkermansia muciniphila and a host, and reveal the action mechanism of the Akkermansia muciniphila in regulating the synthesis of maternal colostrum IgA, thereby providing a theoretical basis for improving the maternal colostrum IgA and further improving the maternal reproductive performance.

The present application relates to a kind of preparation method of Fugunkang composition and its detection method, the preparation method is cut into section, first using red koji and saccharomyces cerevisiae combined fermentation extraction, dregs is extracted with water before boiling, concentrate and extract the fermentation liquor and water, it is obtained.The metabolic function of microorganism is fully utilized, promote the release and absorption of effective components of traditional Chinese medicine in vivo, so as to improve the curative effect of traditional Chinese medicine, reduce the side effect of traditional Chinese medicine.The detection method includes spray agent in just bed, parsnip medicine thin layer identification and the content detection of rutin, hypericin;The thin layer identification can identify just bed and parsnip medicine under the same chromatographic condition, the content detection increases the content detection of hypericin on the basis of original, and the content of rutin and hypericin can be determined simultaneously, save the detection cost, ensure the quality of raw material and finished product.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

The invention discloses a black pepper extract-containing composition capable of promoting intestinal digestion and absorption and a cat food, and relates to the technical field of animal foods.The composition is prepared by compounding fish oil, krill oil, sunflower seed oil and linseed oil according to a specific proportion based on compound functional grease and natural plant extracts in a scientific proportion; according to the invention, the ratio of omega6 fatty acid to omega3 fatty acid is optimized to an ideal range of (2.5-3.2): 1, black pepper extract with functions of promoting digestion and regulating flora is synergistically added, and through combination of scientifically proportioned functional components and an advanced process, an'intestinal tract-microorganism-metabolism 'experiment verifies that digestion and absorption of cat nutrition are realized, and the effect of promoting digestion and regulating flora is achieved. Meanwhile, the multi-dimensional and systematic improvement of oxidation resistance, inflammation resistance, immunity improvement and metabolism functions is achieved.

The invention discloses application of auricularia auricula monomer polysaccharide ME-2 in preparation of drugs for preventing and treating fatty liver diseases related to metabolic dysfunction. The research of the invention systematically proves that ME-2 has a remarkable intervention effect on the whole course of MASLD for the first time. The invention discloses a breakthrough function of ME-2 as a liver metabolism regulator for the first time: by directly correcting liver lipid metabolism disorder (such as regulating core genes such as Srebp-1c, ACC1, FASN and the like), liver fatty degeneration can be relieved in a dose-dependent manner in the whole course of MASLD, and the serum transaminase level and dyslipidemia can be reduced. Importantly, the curative effect of the traditional Chinese medicine is derived from intervention on a metabolic root source, and is totally different from a known anti-inflammatory application mechanism. Meanwhile, ME-2 has the remarkable advantages of being clear in structure, taking metabolic regulation as a core, and being safe and non-toxic, and a brand new drug candidate is provided for prevention and treatment of MASLD.

The invention belongs to the technical field of medical evaluation, and relates to a method for evaluating damage of air pollution to human skin health based on a PPO-LSTM fusion algorithm. The method comprises the following steps: acquiring multi-source data; preprocessing data, and constructing a multi-dimensional time sequence feature data set; establishing a PPO-LSTM fusion model, performing feature extraction and reinforcement learning optimization on the multi-dimensional time sequence features, and outputting skin health core indexes; performing prediction and quantitative evaluation on the functional states of the cuticle, the epidermal layer and the corium layer; generating a personalized nursing decision scheme for skin health maintenance; outputting corresponding early warning information and coping suggestions by judging the risk levels of the skin barrier function and the dermal metabolism function; and updating parameters of the skin health injury evaluation model. According to the method, multi-dimensional data are integrated in the same model at the same time, the evaluation dimension is more comprehensive, the accuracy of skin health injury evaluation is improved, and a complete closed loop from detection evaluation to nursing scheme generation and risk prompt is realized through decision making and early warning.

Metabolic dysfunction–associated steatotic liver disease (MASLD), previously known as non- alcoholic fatty liver disease (NAFLD), is a condition characterized by the accumulation of fat in the liver of individuals with no alcohol consumption, and at least one cardiometabolic risk factor (overweight / obesity, high blood pressure, high blood sugar, high triglycerides levels, low HDL-C levels). The inventors demonstrated that Rab30 silencing improve metabolic dysfunction–associated steatotic liver disease (MASLD). The present invention relates to a method for the treatment of metabolic dysfunction–associated steatotic liver disease (MASLD) in a subject in need thereof comprising the administration of a therapeutically effective amount of an inhibitor of Rab30.

The invention provides a traditional Chinese medicine composition which comprises the following components in parts by weight: 32-34 parts of rumex hanus, 20-31 parts of dandelion, 20-32 parts of uncaria rhynchophylla and 15-35 parts of gastrodia elata. And at least one of the following six traditional Chinese medicines in parts by weight: 17-37 parts of radix paeoniae alba, 15-20 parts of lumbricus, 10-45 parts of eucommia ulmoides, 22-34 parts of longan seeds, 20-37 parts of tribulus terrestris and 10-30 parts of herba siegesbeckiae. The traditional Chinese medicine composition is taken by adopting deuterium-depleted water. The combination of the traditional Chinese medicinal materials has a synergistic effect in the aspects of treating hypertension, hyperlipidemia and metabolic syndrome, the traditional Chinese medicinal materials respectively contain different active ingredients, the overall curative effect is enhanced by regulating blood pressure, blood fat and metabolic functions through multiple targets, and in order to enable the traditional Chinese medicinal composition to better exert the drug effect, the traditional Chinese medicinal composition has a remarkable curative effect. Preferably, the deuterium-depleted water is matched with the traditional Chinese medicine composition to be taken, and the effect of the deuterium-depleted water is developed by 1-2 times.

The invention relates to the technical field of neonatal inherited metabolic disease screening, and discloses a neonatal inherited metabolic disease screening auxiliary system. The system comprises a multi-source information acquisition module, an information standardization module, a dynamic metabolism image construction module, an anomaly detection and analysis module and a screening management optimization module. The system integrates blood metabolites, gene variation, clinical signs and other multi-source information of newborns, constructs a metabolic function image showing dynamic changes and interaction relations of the metabolites, recognizes metabolic abnormality areas and development situations according to the metabolic function image, and generates a personalized screening management plan. Metabolic network visualization analysis is realized through a dynamic image, and an anomaly detection algorithm is continuously optimized by utilizing planned execution feedback data. According to the system, the trend evaluation of the metabolic state and the self-adaptive iteration of the screening strategy are realized, and the screening accuracy and the management individualization level are improved.

Provided herein is a noninvasive method for measuring pH, glucose and glycogen levels using a single acquisition method, as well as systems for performing the method. This method for glycogen / glucose (and pH) detection has high specificity enabled by superior chemical shift separation in high-strength magnetic fields. The methods have applications in detecting changing tumor microenvironments in cancerous cells for measuring important metrics for noninvasive and quantitative metabolic profiling.

The application discloses a kind of composition of adjusting overall metabolic balance, inhibiting cancer cell growth, antitumor, raw material includes ganoderma lucidum, crocodile peptide, astragalus, polypodium pinnatum, ginseng, turmeric, clove, poria cocos, camellia sinensis, rich glutathione yeast, cordyceps militaris, gizzard gold, peach kernel, compound probiotics, brassica campestris l.var.rapa.The application fuses modern medical scientific concept and traditional Chinese medicine "blood stasis and stagnation and cause mass" theory, raw material synergistic effect, by improving blood oxygen content, anti-inflammatory, improve metabolic function, blood circulation and other ways, realize protection mitochondria from damage, anti-mutation;And through the way such as supplementing compound probiotics, regulate intestinal flora, enhance immunity, finally realize soft and hard knot, adjust overall metabolic balance, inhibit cancer cell growth, antitumor, relieve tumor treatment side effect, application prospect is wide.

The preparation method of the biomimetic stratum corneum and the biomimetic skin with tissue-like differentiation structure belongs to the technical field of transdermal drug delivery. Polymer microspheres are dispersed in a lipid mixture to obtain lipid-coated microspheres, and then a polymer-lipid composite film with a brick-mortar-like structure is formed by hot pressing, thereby obtaining a biomimetic stratum corneum highly consistent with the structure of human stratum corneum. The biomimetic stratum corneum not only has anisotropic ultrastructure in the natural stratum corneum, but also shows a permeation barrier function highly consistent with the ex vivo human skin. The biomimetic stratum corneum is co-cultured with an artificial tissue culture skin to prepare a biomimetic skin, so as to introduce skin metabolic function and / or serve as a hair follicle stem cell carrier, and construct a biomimetic skin containing a hair follicle structure. The present application is suitable for in vitro transdermal penetration test and evaluation of drugs and cosmetics, and provides reliable and efficient alternative materials and methods to solve the problems of poor predictability and large individual differences of existing animal skin models.

This invention provides an application of tartary buckwheat antioxidant peptide as a PPARα agonist. The tartary buckwheat antioxidant peptide (SEQ ID NO:1) is used to prepare a PPARα agonist, and this tartary buckwheat antioxidant peptide is used to prepare a drug for improving metabolic dysfunction-related fatty liver disease (MASLD). The tartary buckwheat antioxidant peptide of this invention provides a new drug candidate for improving MASLD and has broad clinical application prospects.

This invention generally relates to a technique for degrading systemic toxins in vivo by enhancing the metabolic function of the lungs. Such a technique involves introducing a composition into the lung tissue of a subject, the composition comprising at least one enzyme known to enzymatically break down at least one toxin systemically present in the subject's body. The provided technique enables the lungs to act as a modulated metabolic organ, thereby promoting the removal of toxins from the systemic circulation of a subject, such as a subject suffering from a condition leading to the accumulation of toxins or endogenous metabolites, or a subject who has ingested toxic substances.

The present disclosure provides methods and compositions for treating a disease or condition involving inflammation and / or fibrosis in the liver, e.g., metabolic dysfunction-associated steatohepatitis (MASH), metabolic dysfunction-associated steatotic liver disease (MASLD), primary biliary cholangitis, primary sclerosing cholangitis, alcoholic cirrhosis, hepatitis cirrhosis, cholestasis, autoimmune hepatitis, viral hepatitis B, viral hepatitis C, hemochromatosis, Wilson's disease, or alcoholic steatohepatitis, with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.

The present invention relates to the use of the Lactobacillus helveticus BGRA43 strain for the prevention and / or treatment of liver diseases and / or liver disorders, preferably metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (N AFLD), and / or for the reduction of liver steatosis. The formulation, preferably for peroral administration, comprising the L. helveticus BGRA43 strain. The formulation comprising the L helveticus BGRA43 strain, which is preferably a probiotic food product intended for human consumption. Lyophilizate of the L helveticus BGRA43 strain, comprising the L. helveticus BGRA43 strain at a concentration from 108 to 1013 CFU / g.

To provide a novel composition that has the effect of maintaining or improving glucose metabolism function. [Solution] A composition for maintaining or improving glucose metabolism function, containing a hexanoic acid compound as an active ingredient.

The invention provides a digestive tract tumor course monitoring system. The system comprises a system control module, a first-stage detection module, a second-stage detection module, a third-stage detection module, a risk assessment module and an intervention decision module. The primary detection module is used for collecting tumor markers, images and clinical symptom data of a patient; the second-stage detection module is used for performing liquid biopsy, pathological biopsy and metabolic function evaluation on the first-stage positive patient; the third-stage detection module is used for carrying out micro-metastasis detection and immune microenvironment and genome analysis on a second-stage positive patient; the risk assessment module determines a patient risk level based on a detection result; the intervention decision module outputs intervention measures based on the risk level; the system control module manages and coordinates operation of all the modules. Each detection module automatically captures detection data by being connected with a hospital system, and judges an abnormal condition according to a set threshold value. According to the system, through a logic mechanism of grading detection and grading intervention, precise monitoring and early warning intervention on the disease course of the digestive tract tumor patient are realized.

A probiotic composition for treating or preventing metabolic dysfunction-associated steatotic liver disease-associated hepatocellular carcinoma(MASLD-HCC) or colorectal cancer, comprises one or more microbiota selected from a group consisting of Lactobacillus helveticus, Lactobacillus plantarum, Lactobacillus rhamnosus GG, Lactobacillus paracasei, Lactobacillus acidophilus, Bifidobacterium breve, Bifidobacterium animalis subsp. Lactis, Streptococcus thermophilus or any combination thereof. The probiotic composition demonstrates improved therapeutic effects when combined with low-dose Sorafenib for MASLD-HCC and outperforms 5-Fluorouracil in colorectal cancer models.

Embodiments of the present application provide a medical image parameter reconstruction method, system, device and medium, relating to the technical field of medical detection, the method comprising: acquiring a suspicious lesion position and structural information of the suspicious lesion of a human body tissue to be measured by an ultrasonic probe in a composite probe; guiding a light source end and an optical detection end of an optical probe in the composite probe to collect optical signals according to the structural information; constructing an optical scattering model according to the structural information and the optical signals; constructing a forward analytical model by using the optical scattering model to obtain an analytical expression of an absorption coefficient and a scattering coefficient of the human body tissue to be measured; performing inverse solution on the analytical expression by using a regression algorithm to obtain a solution parameter of the analytical expression; solving a target parameter according to a solution relationship; and solving the absorption coefficient and the scattering coefficient of the human body tissue to be measured by using the target parameter. The present application can improve the detection accuracy of metabolic function information of a lesion in the human body tissue to be measured.

The application discloses a chrysanthemum stem and leaf active extract with improved fish heavy metal poisoning and a preparation method thereof. The chrysanthemum stem and leaf active extract is compounded by a chrysanthemum stem and leaf crude polysaccharide part and a chrysanthemum stem and leaf phenolic ketone part. The pharmacodynamic experiment results show that the chrysanthemum stem and leaf active extract has a good improvement effect on fish heavy metal poisoning. The chrysanthemum stem and leaf active extract can not only improve pathological changes such as heart and liver granuloma, kidney tubular cast, intestinal cavity expansion and gill lamella shedding caused by heavy metal poisoning, but also improve metabolic dysfunction such as taurine and hypotaurine metabolic disorder, pyruvic acid metabolic abnormality, tricarboxylic acid cycle disorder, glycolysis and gluconeogenesis disorder caused by heavy metal poisoning. The preparation method has reasonable whole preparation process design, can realize waste utilization, extends a chrysanthemum industry chain, expands a chrysanthemum resource utilization approach, is helpful to quality improvement and efficiency increase and green development of the chrysanthemum industry, and provides support for prevention and treatment of heavy metal poisoning.

A polyhydroxyalkanoate (PHA) containing monomer units of 3-hydroxybutyrate for use, by oral administration, in the prevention or treatment of an overweight or obesity condition, or of metabolic dysfunctions related to the condition. A marked effect was observed on the reduction of the body weight, both in the case of a standard diet and in the case of a diet rich in fats, a reduction that can be attributed to an increase in lipid oxidation to the detriment of the deposit of excess lipids, as confirmed by the decrease in the body weight and by analyses of the body composition. A positive effect on the metabolic dysfunctions related to an overweight or obesity condition has also been verified, in particular on dyslipidemias, such as the blood level of low-density lipoproteins (LDL cholesterol) and triglycerides, as well as an improvement in the inflammatory state.

This invention discloses a compound probiotic solid beverage formula that assists in weight control and oil adsorption. The invention designs a beverage formula suitable for human consumption. The compound Chinese herbal medicines and fruit and vegetable powders work together to adsorb oil in the stomach and intestines through physical encapsulation. Hydrolyzed white kidney bean protein blocks starch absorption, and probiotics promote intestinal absorption. Together, they can improve the body's metabolic function and solve health problems such as weight gain caused by greasy diet.

Provided herein are methods for detecting the risk or presence of a metabolic dysfunction or age-related disease in a subject. Also provided herein are methods for identifying a subject at risk or presence in need of treatment of metabolic dysfunction or age-related disease.